» Articles » PMID: 26212251

Idiopathic Interstitial Pneumonias with Connective Tissue Diseases Features: A Review

Overview
Journal Respirology
Specialty Pulmonary Medicine
Date 2015 Jul 28
PMID 26212251
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

A systematic approach is recommended to search for clinical and biological features of connective tissue disease (CTD) in any patient with interstitial lung disease (ILD). In the diagnostic approach to ILD, a diagnosis of CTD should be considered particularly in women and subjects younger than 50 years, and in those with an imaging and/or pathological pattern of non-specific interstitial pneumonia. However, the diagnosis of CTD may be difficult when ILD is the presenting or the dominant manifestation of CTD. A proportion of patients with ILD present symptoms that belong to the spectrum of CTD and/or biological autoimmune features, but do not fulfil diagnostic criteria for a given CTD. Some imaging and histopathological patterns may also suggest the presence of an underlying CTD. Although studies published to date used heterogeneous definitions and terminology for this condition, evidence is accumulating that even limited CTD features are relevant regarding symptoms, imaging features, pathological pattern and possibly evolution to overt CTD, whereas the impact on prognosis needs confirmation. Conversely, autoantibodies alone do not seem to impact the prognosis or management in patients with otherwise typical idiopathic pulmonary fibrosis and no extra-pulmonary manifestation. A collective international multidisciplinary effort has proposed a uniform definition and criteria for 'interstitial pneumonia with autoimmune features', a condition characterized by limited CTD features occurring in the setting of ILD, with the aim of fostering future clinical studies. Referral of ILD patients suspect to have CTD to a rheumatologist and possibly multidisciplinary discussion may contribute to a better management.

Citing Articles

Deregulated immune cell recruitment orchestrated by c-MET impairs pulmonary inflammation and fibrosis.

Barbosa-Matos C, Borges-Pereira C, Liborio-Ramos S, Fernandes R, Oliveira M, Mendes-Frias A Respir Res. 2024; 25(1):257.

PMID: 38909206 PMC: 11193258. DOI: 10.1186/s12931-024-02884-1.


Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment.

Althobiani M, Russell A, Jacob J, Ranjan Y, Folarin A, Hurst J Front Med (Lausanne). 2024; 11:1296890.

PMID: 38698783 PMC: 11063378. DOI: 10.3389/fmed.2024.1296890.


The Pattern and Progression of "Usual" Interstitial Pneumonia with Autoimmune Features: Comparison with Patients with Classic Interstitial Pneumonia with Autoimmune Features and Idiopathic Pulmonary Fibrosis.

Libra A, Colaci M, Spicuzza L, Luca G, Fischetti S, Pashalidis G J Clin Med. 2024; 13(2).

PMID: 38256503 PMC: 10816405. DOI: 10.3390/jcm13020369.


E-Selectin, ICAM-1, and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases.

Pulito-Cueto V, Remuzgo-Martinez S, Genre F, Atienza-Mateo B, Mora-Cuesta V, Iturbe-Fernandez D Int J Mol Sci. 2023; 24(15).

PMID: 37569893 PMC: 10420063. DOI: 10.3390/ijms241512518.


The Evolving Concept of the Multidisciplinary Approach in the Diagnosis and Management of Interstitial Lung Diseases.

Sanduzzi Zamparelli S, Sanduzzi Zamparelli A, Bocchino M Diagnostics (Basel). 2023; 13(14).

PMID: 37510180 PMC: 10378270. DOI: 10.3390/diagnostics13142437.